119th (2025–2027)
H.R. 7867
This bill strengthens safety standards for infant formula by requiring manufacturers to conduct regular testing for dangerous pathogens and microorganisms—including botulism bacteria—in both their manufacturing facilities and finished products. Manufacturers must notify the FDA within one business day of any positive test results and keep detailed records for inspection purposes. The bill also requires the FDA to establish consistent inspection standards for all infant formula products regardless of their origin and mandates that Congress be notified within one business day when the FDA receives reports of positive pathogen tests or issues enforcement actions against formula manufacturers. The FDA must issue final regulations implementing these requirements within 90 days of the bill's enactment, with no specific funding allocated in the legislation itself.